FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

FDA granted accelerated approval for Modeyso (dordaviprone) for the treatment of adult and pediatric patients (1 year of age and older) with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

August 08, 2025

Vol.51 No.31

Clinical Trials & Tribulations

The other side of the patient portal: Reflections from a cancer center leader

It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.”

AACR names 2025 fellows of AACR Academy, AACR Academy president

The American Association for Cancer Research named its newly elected 2025 class of fellows of the AACR Academy.

March 14, 2025

Vol.51 No.10

In Brief

Becky Kamowitz named executive director of the Skin Cancer Foundation

Becky Kamowitz was named executive director of the Skin Cancer Foundation, a national nonprofit organization that is committed to decreasing the incidence and mortality skin cancer through public education. Kamowitz has worked for the foundation for more than a decade and previously served as interim executive director and senior director of marketing communications.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

FDA approved Unloxcyt (osibelimab-ipdl), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.

October 11, 2024

Vol.50 No.38

FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma

YOU MAY BE INTERESTED IN

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

The other side of the patient portal: Reflections from a cancer center leader

AACR names 2025 fellows of AACR Academy, AACR Academy president

Becky Kamowitz named executive director of the Skin Cancer Foundation

FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Renew today!

Subscriber content

Never miss an issue!

Login